Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GLUD1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GLUD1 Recombinant Protein / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for enzymatic assays. |
View GLUD1 Products |
| Gene Delivery | GLUD1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and metabolic flux analysis. |
View GLUD1 Products |
| Benchmark Ab | Anti-GLUD1 Recombinant Antibody Recombinant positive control for Western Blot and Immunohistochemistry. |
View GLUD1 Products |
| Validator | GLUD1 siRNA Set For knockdown verification in tumor cell lines. |
View GLUD1 Products |
| Related Target A | GLUD2 Highly homologous isoform (97% identity). Crucial for off-target selectivity screening to prevent neurotoxicity. |
View GLUD2 Products |
| Related Target B | SIRT3 Mitochondrial deacetylase that deacetylates and activates GLUD1. Essential for regulatory pathway studies. |
View SIRT3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homolog panel screening (GLUD1 vs GLUD2) | Human GLUD1 and GLUD2 recombinant proteins strictly verified by mass spectrometry and sequence analysis. |
| Allosteric regulation assessment (GTP/ADP) | Recombinant proteins expressed with native-like tertiary structure to preserve regulatory binding sites. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and reference materials included. |
| False Positives | Validated siRNA pool included for target specificity and knockdown verification. |
Live GLUD1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GLUD1 therapeutics is intensifying, with major players shifting focus from traditional metabolic enzymes to targeting glutaminolysis in solid tumors. As first-generation allosteric inhibitors reach the preclinical and early clinical stages, the next wave of R&D is targeting drug-resistant tumor microenvironments through combination therapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutions, Biotech Startups | Glioblastoma, Breast Cancer, Hyperinsulinism | Enzymatic Inhibition Assay (Need high-purity, active recombinant GLUD1) |
| Combination Therapies | Oncology-focused Biopharma | Refractory Solid Tumors | Pathway Validation (Need GLUD1 siRNA and SIRT3/GLS partner proteins) |
| Gene Therapy / RNAi | RNA Therapeutics Developers | Hyperinsulinism-Hyperammonemia (HI/HA) | Target Knockdown Verification (Need GLUD1 Lentivirus/siRNA) |